SecBot SecBot
PRESS-RELEASE ·Filed Apr 3, 2026

DNLI

Denali Therapeutics Inc.
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ◆ Mixed

The termination removes a major partner but gives Denali full upside from DNL593. Investors should monitor for data readouts by end of 2026 as the next catalyst. Increased R&D burden may pressure cash, raising potential for future dilution unless new partnerships emerge.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.38
T+0 close · Apr 3, 2026 · via day close
Latest settled
+34.06%
T+60 · $25.98
Vs SPY
+20.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $19.38entry
  2. T+1 · 7mo ago +0.15%α +0.09% · $19.41
  3. T+5 · 7mo ago +0.21%α −3.93% · $19.42
  4. T+20 · 7mo ago −3.66%α −12.65% · $18.67
  5. T+60 · 5mo ago +34.06%α +20.59% · $25.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Denali Therapeutics announced that Takeda has terminated their collaboration on DNL593, an investigational therapy for frontotemporal dementia caused by granulin mutations (FTD-GRN), for strategic reasons unrelated to safety or efficacy. Denali will now advance DNL593 independently, with Phase 1/2 trial results expected by the end of 2026. The company retains full rights to the program and its proprietary TransportVehicle™ platform, which enables blood-brain barrier penetration.

Key Facts

  • Takeda terminated its collaboration with Denali on DNL593 for strategic reasons, not due to safety or efficacy concerns.
  • Denali regains full control of DNL593 and its intellectual property, allowing independent development.
  • Phase 1/2 trial in FTD-GRN patients is fully enrolled (n=40), with data expected by end of 2026.
  • Interim data in healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin, indicating brain delivery.
  • DNL593 was generally well tolerated with no significant safety signals to date.

Financial Impact

Potential increase in R&D spend as Denali assumes full development costs; loss of Takeda funding offsets by retained economics.

R&D expensecash runwaydilution riskfuture revenue potential

Risk Factors

  • Increased financial burden from funding DNL593 development alone.
  • Clinical data may not translate into meaningful clinical benefit despite positive biomarker signals.
  • Regulatory uncertainty for FTD-GRN therapies, with no approved treatments to benchmark against.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3268105

Track record

17 reports on DNLI

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026